Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMADA 2000: Devimistat in Older Patients with R/R AML
NCT03504410Phase 3Terminated
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of devimistat in acute myeloid leukemia (AML) (2 arms), sponsored by Cornerstone Pharmaceuticals. Primary endpoint: Complete Remission at 12 months. Started Nov 2018; status: terminated.
02
Drugs
devimistat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03504410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504410.